{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:59:48Z","timestamp":1787795988264,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:00:00Z","timestamp":1320969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:00:00Z","timestamp":1320969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/cgt.2011.70","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T11:22:08Z","timestamp":1321010528000},"page":"160-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation"],"prefix":"10.1038","volume":"19","author":[{"given":"S","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B C","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J G","family":"Supko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"McGinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lanuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K K","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,11]]},"reference":[{"key":"BFcgt201170_CR1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nrc1750","volume":"5","author":"KA Parato","year":"2005","unstructured":"Parato KA, Senger D, Forsyth PA, Bell JC . Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965\u2013976.","journal-title":"Nat Rev Cancer"},{"key":"BFcgt201170_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrmicro1927","volume":"6","author":"R Cattaneo","year":"2008","unstructured":"Cattaneo R, Miest T, Shashkova EV, Barry MA . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529\u2013540.","journal-title":"Nat Rev Microbiol"},{"key":"BFcgt201170_CR3","first-page":"6070","volume":"62","author":"T Reid","year":"2002","unstructured":"Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070\u20136079.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2010.020","volume":"21","author":"SK Geevarghese","year":"2010","unstructured":"Geevarghese SK, Geller DA, de Haan HA, H\u00f6rer M, Knoll AE, Mescheder A et al. Phase I\/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21: 1119\u20131128.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201170_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533\u2013542.","journal-title":"Lancet Oncol"},{"key":"BFcgt201170_CR6","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763\u20135771.","journal-title":"J Clin Oncol"},{"key":"BFcgt201170_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/mt.2008.240","volume":"17","author":"Y Fong","year":"2009","unstructured":"Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389\u2013394.","journal-title":"Mol Ther"},{"key":"BFcgt201170_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"3","author":"C Heise","year":"1997","unstructured":"Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639\u2013645.","journal-title":"Nat Med"},{"key":"BFcgt201170_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","volume":"6","author":"FR Khuri","year":"2000","unstructured":"Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879\u2013885.","journal-title":"Nat Med"},{"key":"BFcgt201170_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nbt0598-444","volume":"16","author":"M Chase","year":"1998","unstructured":"Chase M, Chung R, Chiocca EA . An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotech 1998; 16: 444\u2013448.","journal-title":"Nat Biotech"},{"key":"BFcgt201170_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/cncr.10776","volume":"95","author":"TM Pawlik","year":"2002","unstructured":"Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171\u20131181.","journal-title":"Cancer"},{"key":"BFcgt201170_CR12","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1158\/0008-5472.CAN-05-0154","volume":"65","author":"E Tyminski","year":"2005","unstructured":"Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005; 65: 6850\u20136857.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR13","first-page":"5447","volume":"61","author":"H Nakamura","year":"2001","unstructured":"Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK . Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447\u20135452.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR14","first-page":"5274","volume":"53","author":"SM Freeman","year":"1993","unstructured":"Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The \u2018bystander effect\u2019: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274\u20135283.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.gt.3301237","volume":"7","author":"JA McCart","year":"2000","unstructured":"McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR et al. Complex interactions between the replicating oncolytic effect and the enzyme\/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217\u20131223.","journal-title":"Gene Ther"},{"key":"BFcgt201170_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/jnci\/djj003","volume":"98","author":"M Aghi","year":"2006","unstructured":"Aghi M, Rabkin S, Martuza RL . Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38\u201350.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt201170_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1006\/jsre.1997.5089","volume":"69","author":"NM Carroll","year":"1997","unstructured":"Carroll NM, Chiocca EA, Tanabe KK . The effect of ganciclovir on herpes simlex virus-mediated oncolysis. J Surg Res 1997; 69: 413\u2013417.","journal-title":"J Surg Res"},{"key":"BFcgt201170_CR18","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-05-4352","volume":"66","author":"GR Simpson","year":"2006","unstructured":"Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS . Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835\u20134842.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cgt.7700978","volume":"14","author":"MB Guffey","year":"2007","unstructured":"Guffey MB, Parker JN, Luckett Jr WS, Gillespie GY, Meleth S, Whitley RJ et al. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther 2007; 14: 45\u201356.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201170_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/gt.2008.82","volume":"15","author":"J Foloppe","year":"2008","unstructured":"Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15: 1361\u20131371.","journal-title":"Gene Ther"},{"key":"BFcgt201170_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1472-6750-6-40","volume":"6","author":"T Kuroda","year":"2006","unstructured":"Kuroda T, Martuza RL, Todo T, Rabkin SD . Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 2006; 6: 40.","journal-title":"BMC Biotechnol"},{"key":"BFcgt201170_CR22","first-page":"3813","volume":"60","author":"P Erbs","year":"2000","unstructured":"Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase\/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813\u20133822.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/sj.cgt.7700189","volume":"7","author":"F Koyama","year":"2000","unstructured":"Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H . Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015\u20131022.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201170_CR24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/sj.gt.3301557","volume":"8","author":"GA Chung-Faye","year":"2001","unstructured":"Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547\u20131554.","journal-title":"Gene Ther"},{"key":"BFcgt201170_CR25","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1158\/0008-5472.CAN-06-2744","volume":"66","author":"T Kuroda","year":"2006","unstructured":"Kuroda T, Rabkin SD, Martuza RL . Effective treatment of tumors with strong beta-catenin\/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 10127\u201310135.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jpba.2005.01.039","volume":"38","author":"R Pisano","year":"2005","unstructured":"Pisano R, Breda M, Grassi S, James CA . Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues. J Pharm Biomed Anal 2005; 38: 738\u2013745.","journal-title":"J Pharm Biomed Anal"},{"key":"BFcgt201170_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jms.840","volume":"40","author":"L Sabatini","year":"2005","unstructured":"Sabatini L, Barbieri A, Tosi M, Violante FS . A new high-performance liquid chromatographic\/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom 2005; 40: 669\u2013674.","journal-title":"J Mass Spectrom"},{"key":"BFcgt201170_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1023\/A:1007669411738","volume":"17","author":"VP Shah","year":"2000","unstructured":"Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ et al. Bioanalytical method validation\u2014a revisit with a decade of progress. Pharm Res 2000; 17: 1551\u20131557.","journal-title":"Pharm Res"},{"key":"BFcgt201170_CR29","first-page":"2790","volume":"60","author":"TM Pawlik","year":"2000","unstructured":"Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790\u20132795.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.neo.7900016","volume":"1","author":"A Chahlavi","year":"1999","unstructured":"Chahlavi A, Todo T, Martuza RL, Rabkin SD . Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162\u2013169.","journal-title":"Neoplasia"},{"key":"BFcgt201170_CR31","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1089\/10430349950016410","volume":"10","author":"T Toyoizumi","year":"1999","unstructured":"Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL . Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013\u20133029.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201170_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1566523044577988","volume":"4","author":"DE Post","year":"2004","unstructured":"Post DE, Fulci G, Chiocca EA, Van Meir EG . Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004; 4: 41\u201351.","journal-title":"Curr Gene Ther"},{"key":"BFcgt201170_CR33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/jgm.700","volume":"7","author":"K Nakano","year":"2005","unstructured":"Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB et al. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J Gene Med 2005; 7: 638\u2013648.","journal-title":"J Gene Med"},{"key":"BFcgt201170_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1089\/hum.2006.17.1241","volume":"17","author":"A Gutermann","year":"2006","unstructured":"Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241\u20131253.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201170_CR35","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1128\/JVI.75.15.7050-7058.2001","volume":"75","author":"H Petrowsky","year":"2001","unstructured":"Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001; 75: 7050\u20137058.","journal-title":"J Virol"},{"key":"BFcgt201170_CR36","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.gassur.2005.06.024","volume":"9","author":"DP Eisenberg","year":"2005","unstructured":"Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005; 9: 1068\u20131077; discussion 77\u201379.","journal-title":"J Gastrointest Surg"},{"key":"BFcgt201170_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","volume":"5","author":"PS Adusumilli","year":"2006","unstructured":"Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006; 5: 48\u201353.","journal-title":"Cancer Biol Ther"},{"key":"BFcgt201170_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/73219","volume":"6","author":"R Weissleder","year":"2000","unstructured":"Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA et al. In vivo magnetic resonance imaging of transgene expression. Nature Med 2000; 6: 351\u2013355.","journal-title":"Nature Med"},{"key":"BFcgt201170_CR39","first-page":"2983","volume":"61","author":"A Jacobs","year":"2001","unstructured":"Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61: 2983\u20132995.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR40","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-06-4062","volume":"67","author":"D Kuruppu","year":"2007","unstructured":"Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y et al. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007; 67: 3295\u20133300.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR41","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1158\/0008-5472.CAN-07-6028","volume":"68","author":"TP Gade","year":"2008","unstructured":"Gade TP, Koutcher JA, Spees WM, Beattie BJ, Ponomarev V, Doubrovin M et al. Imaging transgene activity in vivo. Cancer Res 2008; 68: 2878\u20132884.","journal-title":"Cancer Res"},{"key":"BFcgt201170_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/10430340152712638","volume":"13","author":"BG Harvey","year":"2002","unstructured":"Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15\u201363.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201170_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.cgt.7700750","volume":"12","author":"C Conrad","year":"2005","unstructured":"Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005; 12: 284\u2013294.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201170_CR44","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/ijc.25383","volume":"127","author":"DY Chang","year":"2010","unstructured":"Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975\u20131983.","journal-title":"Int J Cancer"},{"key":"BFcgt201170_CR45","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-09-2974","volume":"16","author":"JD Dias","year":"2010","unstructured":"Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010; 16: 2540\u20132549.","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201170","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:13:20Z","timestamp":1661246000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFcgt201170"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2011.70","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,11]]},"assertion":[{"value":"1 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}